1. Home
  2. MTEM vs MYNZ Comparison

MTEM vs MYNZ Comparison

Compare MTEM & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTEM
  • MYNZ
  • Stock Information
  • Founded
  • MTEM N/A
  • MYNZ 2021
  • Country
  • MTEM United States
  • MYNZ Germany
  • Employees
  • MTEM N/A
  • MYNZ N/A
  • Industry
  • MTEM Biotechnology: Biological Products (No Diagnostic Substances)
  • MYNZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • MTEM Health Care
  • MYNZ Health Care
  • Exchange
  • MTEM Nasdaq
  • MYNZ Nasdaq
  • Market Cap
  • MTEM 8.5M
  • MYNZ 9.8M
  • IPO Year
  • MTEM N/A
  • MYNZ 2021
  • Fundamental
  • Price
  • MTEM $1.43
  • MYNZ $0.38
  • Analyst Decision
  • MTEM
  • MYNZ Buy
  • Analyst Count
  • MTEM 0
  • MYNZ 2
  • Target Price
  • MTEM N/A
  • MYNZ $3.00
  • AVG Volume (30 Days)
  • MTEM 25.6K
  • MYNZ 1.4M
  • Earning Date
  • MTEM 08-08-2024
  • MYNZ 08-13-2024
  • Dividend Yield
  • MTEM N/A
  • MYNZ N/A
  • EPS Growth
  • MTEM N/A
  • MYNZ N/A
  • EPS
  • MTEM N/A
  • MYNZ N/A
  • Revenue
  • MTEM $31,763,000.00
  • MYNZ $895,479.00
  • Revenue This Year
  • MTEM N/A
  • MYNZ $67.40
  • Revenue Next Year
  • MTEM N/A
  • MYNZ $191.13
  • P/E Ratio
  • MTEM N/A
  • MYNZ N/A
  • Revenue Growth
  • MTEM N/A
  • MYNZ 69.00
  • 52 Week Low
  • MTEM $1.01
  • MYNZ $0.32
  • 52 Week High
  • MTEM $9.45
  • MYNZ $4.79
  • Technical
  • Relative Strength Index (RSI)
  • MTEM 61.41
  • MYNZ 39.67
  • Support Level
  • MTEM $1.21
  • MYNZ $0.39
  • Resistance Level
  • MTEM $1.28
  • MYNZ $0.46
  • Average True Range (ATR)
  • MTEM 0.11
  • MYNZ 0.08
  • MACD
  • MTEM 0.03
  • MYNZ 0.01
  • Stochastic Oscillator
  • MTEM 85.37
  • MYNZ 26.53

About MTEM Molecular Templates Inc.

Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Share on Social Networks: